10 million people in the U.S. suffer from lower-limb peripheral arterial disease

NewsGuard 100/100 Score

According to iData Research, an international medical device & dental market research firm, an estimated 10 million people in the U.S. suffer from lower-limb Peripheral Arterial Disease (PAD), with less than 20% of these diagnosed by a physician.

As early detection increases and more patients seek treatment, the U.S. market for peripheral vascular treatment will grow to an estimated $4.7 billion by 2015.

PAD is the formation of plaque in arterial blood vessels of the outer circulatory system. This causes damage to the arterial wall, which increases the risk of stroke. In 2008, over 4 million individuals in the U.S. had symptoms indicative of PAD, such as persistent leg cramping, numbness, fatigue and severe pain.

"Of people aged 50 to 69 with a history of smoking or diabetes, approximately 30% will manifest PAD," says Kamran Zamanian PhD., CEO of iData Research, "This will drive sales for PAD treatment devices, particularly for devices such as stents and stent-grafts, and complementary and alternative products, like embolic protection and atherectomy devices."

In 2008, the largest segment in the U.S. market for peripheral vascular devices was for stents, which represented 28.7% of the overall treatment market. The stent market will grow at double digit rates through 2015, led by an increase in early diagnoses. The U.S. government and the medical community have taken an active role in improving awareness of PAD among physicians and the general population.

iData Research provides market intelligence reports on the peripheral vascular device market, for the U.S., Europe and Japan. Watch the iData movie at: www.idataresearch.net/discoveridata.html

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Rising antibiotic resistance prompts shift to ecological research strategies in infection control